vs
Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.8M, roughly 1.1× MAXCYTE, INC.). MAXCYTE, INC. runs the higher net margin — -200.5% vs -507.8%, a 307.3% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -20.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -7.4%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
MXCT vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $5.5M |
| Net Profit | $-9.6M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -234.5% | -516.0% |
| Net Margin | -200.5% | -507.8% |
| Revenue YoY | -20.9% | 171.3% |
| Net Profit YoY | 9.4% | -48.3% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $5.5M | ||
| Q3 25 | $4.6M | $0 | ||
| Q2 25 | $5.8M | $2.0M | ||
| Q1 25 | $5.7M | $2.3M | ||
| Q4 24 | $6.1M | $2.0M | ||
| Q3 24 | $5.6M | $1.8M | ||
| Q2 24 | $5.0M | $1.1M | ||
| Q1 24 | $5.6M | $3.4M |
| Q4 25 | $-9.6M | $-27.9M | ||
| Q3 25 | $-12.4M | $-32.7M | ||
| Q2 25 | $-12.4M | $-26.9M | ||
| Q1 25 | $-10.3M | $-21.5M | ||
| Q4 24 | $-10.6M | $-18.8M | ||
| Q3 24 | $-11.6M | $-25.5M | ||
| Q2 24 | $-9.4M | $-20.9M | ||
| Q1 24 | $-9.5M | $-24.1M |
| Q4 25 | -234.5% | -516.0% | ||
| Q3 25 | -307.4% | — | ||
| Q2 25 | -244.3% | -1347.1% | ||
| Q1 25 | -214.1% | -930.5% | ||
| Q4 24 | -213.1% | -985.8% | ||
| Q3 24 | -250.4% | -1448.4% | ||
| Q2 24 | -241.0% | -1915.4% | ||
| Q1 24 | -219.8% | -713.3% |
| Q4 25 | -200.5% | -507.8% | ||
| Q3 25 | -269.7% | — | ||
| Q2 25 | -212.2% | -1353.6% | ||
| Q1 25 | -178.7% | -935.2% | ||
| Q4 24 | -175.0% | -929.0% | ||
| Q3 24 | -205.9% | -1427.5% | ||
| Q2 24 | -188.8% | -1882.0% | ||
| Q1 24 | -170.6% | -705.4% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.12 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | $-0.11 | $-0.10 | ||
| Q2 24 | $-0.09 | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.5M | $246.9M |
| Total Assets | $202.5M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.0M | $319.8M | ||
| Q3 25 | $105.7M | $297.3M | ||
| Q2 25 | $126.6M | $312.8M | ||
| Q1 25 | $138.3M | $116.6M | ||
| Q4 24 | $154.5M | $139.0M | ||
| Q3 24 | $153.8M | $157.7M | ||
| Q2 24 | $157.3M | $172.7M | ||
| Q1 24 | $157.5M | $124.0M |
| Q4 25 | $171.5M | $246.9M | ||
| Q3 25 | $180.3M | $219.0M | ||
| Q2 25 | $190.7M | $248.7M | ||
| Q1 25 | $199.4M | $55.1M | ||
| Q4 24 | $206.3M | $71.5M | ||
| Q3 24 | $213.3M | $88.8M | ||
| Q2 24 | $221.3M | $108.9M | ||
| Q1 24 | $226.4M | $53.8M |
| Q4 25 | $202.5M | $343.3M | ||
| Q3 25 | $213.5M | $316.6M | ||
| Q2 25 | $219.8M | $333.3M | ||
| Q1 25 | $230.0M | $138.4M | ||
| Q4 24 | $239.5M | $160.4M | ||
| Q3 24 | $248.6M | $180.2M | ||
| Q2 24 | $251.5M | $200.4M | ||
| Q1 24 | $257.9M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | $-26.7M |
| Free Cash FlowOCF − Capex | $-2.9M | — |
| FCF MarginFCF / Revenue | -61.0% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-36.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.7M | $-26.7M | ||
| Q3 25 | $-7.5M | $-24.2M | ||
| Q2 25 | $-9.9M | $-20.2M | ||
| Q1 25 | $-14.4M | $-22.0M | ||
| Q4 24 | $-7.8M | $-18.3M | ||
| Q3 24 | $-4.4M | $-21.6M | ||
| Q2 24 | $-4.8M | $-21.5M | ||
| Q1 24 | $-10.6M | $-19.8M |
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $-7.8M | $-24.3M | ||
| Q2 25 | $-10.4M | — | ||
| Q1 25 | $-15.1M | — | ||
| Q4 24 | $-8.0M | $-18.3M | ||
| Q3 24 | $-4.8M | $-21.6M | ||
| Q2 24 | $-5.1M | $-21.7M | ||
| Q1 24 | $-11.4M | $-19.9M |
| Q4 25 | -61.0% | — | ||
| Q3 25 | -168.5% | — | ||
| Q2 25 | -179.2% | — | ||
| Q1 25 | -262.3% | — | ||
| Q4 24 | -131.6% | -905.5% | ||
| Q3 24 | -85.5% | -1210.9% | ||
| Q2 24 | -103.3% | -1951.9% | ||
| Q1 24 | -203.6% | -584.5% |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 6.5% | — | ||
| Q2 25 | 10.0% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 2.4% | 0.1% | ||
| Q3 24 | 7.2% | 2.0% | ||
| Q2 24 | 5.9% | 18.1% | ||
| Q1 24 | 14.4% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
TSHA
Segment breakdown not available.
